IceCure's ProSense Revenue Jumps 30% as Cryoablation Gains Traction in Breast Cancer Treatment
Event summary
- IceCure's U.S. ProSense revenue increased over 30% in Q1 2026 compared to Q1 2025.
- FDA cleared ProSense for low-risk breast cancer treatment in women 70+ in October 2025.
- Massachusetts General Hospital study showed 50% cost reduction with cryoablation vs. lumpectomy.
- IceCure exhibited at Society of Breast Imaging Symposium 2026 with hands-on physician training.
- Company expects to close new system sales in Q2 2026.
The big picture
IceCure's strong Q1 2026 revenue growth reflects the accelerating adoption of cryoablation as a cost-effective alternative to surgical tumor removal. The technology's alignment with value-based care models and its potential to expand the role of radiologists in cancer treatment position it for broader market penetration. The company's participation in key medical conferences and hands-on physician training workshops further supports its commercial momentum.
What we're watching
- Adoption Pace
- How quickly ProSense will be adopted at leading academic and research hospitals following FDA clearance.
- Cost Efficiency
- Whether the 50% cost reduction demonstrated in the Massachusetts General Hospital study will drive broader insurance coverage and patient access.
- Regulatory Expansion
- The pace at which IceCure can secure additional regulatory approvals for ProSense in other cancer indications beyond breast cancer.
Related topics